On June 23, 2020 Goodwin’s Life Sciences group presented the second of four weekly webinars aiming to provide a multidisciplinary outlook on top-of-mind issues facing European life sciences companies in the era of COVID-19.
At this event, Goodwin Life Sciences partner Robert Puopolo moderated a conversation with Goodwin FDA Regulatory partner Julie Tibbets, Goodwin Licensing + UK Regulatory partner Tim Worden, and Parexel International's Dr. Oliver Fuhrmann, which was focused on FDA and EMA developments and guidance on product development, clinical trials, and trial management in light of the ongoing COVID-19 pandemic.
View The Recording:
Visit Goodwin’s Coronavirus Knowledge Center, where firm lawyers from across the globe are issuing new guidance and insights to help clients fully understand and assess the ramifications of COVID-19 and navigate the potential effects of the outbreak on their businesses.
Robert E. PuopoloPartner
Julie TibbetsPartnerChair, Life Sciences Regulatory & Compliance Practice